Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (131-140 of 715) with videos related to

Pageof 72
Sort By:
Seminars in Thrombosis and Hemostasis|April 1, 1988
Fibrinolysis and atherosclerosisD Collen, I Juhan-Vague
Blut|October 1, 1988
New strategies in the development of thrombolytic agentsH R Lijnen, D Collen
Lancet (London, England)|May 16, 1992
After ISIS-3B E Sobel, D Collen
La Ricerca in Clinica E in Laboratorio|July 1, 1984
The pathophysiological role of fibrinolysis inhibitorsH R Lijnen, D Collen
Biotechnology (Reading, Mass.)|January 1, 1991
Recombinant tissue-type plasminogen activatorD Collen, W F Bennett
Thrombosis and Haemostasis|July 1, 1995
Fibrinolytic agents: mechanisms of activity and pharmacologyH R Lijnen, D Collen
Journal of Medicine|January 1, 1985
Protease inhibitors of human plasma. Alpha-2-antiplasminH R Lijnen, D Collen
Biotechnology Therapeutics|January 1, 1989
Tissue-type plasminogen activator: mutants, variants, and adjunctive treatmentH R Lijnen, D Collen
Biochemical Pharmacology|July 15, 1990
Molecular mechanisms of thrombolysis: implications for therapyD Collen, H R Lijnen
Cardiovascular Research|January 31, 1998
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosisR D Gerard, D Collen
Pageof 72

Showing results (131-140 of 715) with videos related to

Sort By:
Pageof 72
Seminars in Thrombosis and Hemostasis|April 1, 1988
Fibrinolysis and atherosclerosisD Collen, I Juhan-Vague
Blut|October 1, 1988
New strategies in the development of thrombolytic agentsH R Lijnen, D Collen
Lancet (London, England)|May 16, 1992
After ISIS-3B E Sobel, D Collen
La Ricerca in Clinica E in Laboratorio|July 1, 1984
The pathophysiological role of fibrinolysis inhibitorsH R Lijnen, D Collen
Biotechnology (Reading, Mass.)|January 1, 1991
Recombinant tissue-type plasminogen activatorD Collen, W F Bennett
Thrombosis and Haemostasis|July 1, 1995
Fibrinolytic agents: mechanisms of activity and pharmacologyH R Lijnen, D Collen
Journal of Medicine|January 1, 1985
Protease inhibitors of human plasma. Alpha-2-antiplasminH R Lijnen, D Collen
Biotechnology Therapeutics|January 1, 1989
Tissue-type plasminogen activator: mutants, variants, and adjunctive treatmentH R Lijnen, D Collen
Biochemical Pharmacology|July 15, 1990
Molecular mechanisms of thrombolysis: implications for therapyD Collen, H R Lijnen
Cardiovascular Research|January 31, 1998
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosisR D Gerard, D Collen
Pageof 72